Effects of hyperhomocysteinaemia and metabolic syndrome on reproduction in women with polycystic ovary syndrome: a secondary analysis. Issue 6 (June 2019)

• Record Type: Journal Article
• Authors: Chang, Hui; Xie, Liangzhen; Ge, Hang; Wu, Qi; Wen, Yan; Zhang, Duojia; Zhang, Yuehui; Ma, Hongli; Gao, Jingshu; Wang, Chi Chiu; Stener-Victorin, Elisabet; Ng, Ernest HY; Wu, Xiaoke
• Is Part Of: Reproductive biomedicine online. Volume 38:Issue 6(2019)
• Page Start: 990
• Page End: 998
• Publication Date: 2019-06
• Subjects: Hyperhomocysteinemia -- Metabolic syndrome -- Polycystic ovary syndrome -- Reproductive outcomes; Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2018.12.046
• Languages: English
• ISSNs: 1472-6483

Abstract

Abstract: Research question: What is the association between hyperhomocysteinaemia (HHCY), metabolic syndrome, and reproductive outcomes among women with polycystic ovary syndrome (PCOS). Design: A secondary analysis of PCOSAct with 21 sites in China. A total of 1000 women with PCOS were enrolled; 936 women with baseline homocysteine (HCY) were analysed. Results: Higher HCY was associated with higher body mass index, free testosterone and lower FSH, fasting glucose ( P < 0.001; P < 0.001; P = 0.005; P < 0.001) and ovulation rate among all participants (OR 0.59, 95% CI 0.41 to 0.86; OR 0.57, 95% CI 0.39 to 0.83 tertiles 2 and 3 versus tertile 1, respectively). The HHCY group had lower oestradiol and higher free testosterone ( P = 0.04; P < 0.001) than the controls. In the metabolic syndrome group, LH, LH–FSH ratio and sex hormone-binding globulin were lowest in the metabolic syndrome group (all P < 0.001). In the HHCY group, ovulation rate decreased and the second or third trimester pregnancy loss rate increased compared with controls (OR 1.678, 95% CI 1.04 to 2.70; OR 0.03, 95% CI 0.00 to 0.42) with treatment adjustment. Compared with the controls, ovulation, conception, pregnancy, second or third trimester pregnancy loss and live birth rates were statistically lower in the metabolic syndrome group after adjusting treatment (OR 1.76, 95% CI 1.15 to 2.70; OR 1.75, 95% CI 1.15 to 2.65; OR 2.09, 95% CI 1.27 to 3.44; OR 0.02, 95% CI 0.00 to 0.33; OR 2.42 95% CI 1.42 to 4.10), and pregnancy, pregnancy loss and live birth rates remained significantly different after adjusting for treatment and sex-hormone factors (OR 1.77, 95% CI 1.05 to 2.99; OR 0.14, 95% CI 0.02 to 0.82; OR 2.02, 95% CI 1.16 to 3.50). Conclusions: In women with PCOS, HHCY contributes to increased pregnancy loss and reduced ovulation, and metabolic syndrome was related to defects in ovulation, conception, pregnancy, pregnancy loss and live birth, indicating that the two conditions lead to defects at various reproductive stages.